ConsumerMedical competitors

Frederick Howe is Chairman, Chief Executive Officer and founder of MedImpact Healthcare Systems, Inc., the nation's largest privately held full-service pharmacy benefit manager, with 47 million covered lives. Over three decades, Mr. Howe's vision has led to technological breakthroughs and other important changes in the way pharmacy claims are processed and paid every day for millions of consumers. Today, under his leadership, MedImpact is at the forefront of developing new ways to use formularies, disease management and medical data to improve the quality and value of healthcare. He has served on the Schering-Plough Advisory Board and the Scripps Foundation for Medicine and Science, and is an active member in the Academy of Managed Care Pharmacy and several other industry organizations. A dedicated philanthropist, Mr. Howe supports the American Red Cross, Rady Children's Hospital of San Diego, the Leukemia & Lymphoma Society of America, March of Dimes, and the Make-A-Wish Foundation, among many others.

Mohan Ananda was the founding Chairman, CEO, and President of Stamps.com (Nasdaq: STMP) and he currently sits on its Board of Directors. Stamps.com is the leading provider of Internet-based mailing and shipping solutions and was the first ever USPS-licensed vendor to offer PC Postage® in a software-only business model. Stamps.com utilizes technology developed by Dr. Ananda that is protected by a number of U.S. patents. Dr. Ananda was instrumental in raising more than $450 million of capital for the company through private and public offerings.

Mike S. Perry was appointed as Chief Executive Officer (CEO) of AVITA Medical in June 2017, after serving on the Board since February 2013. He brings extensive experience across the global pharmaceutical value chain for healthcare products spanning diverse therapeutic areas, including substantial expertise in cell therapies and cell-based gene therapies. In his career, he has been materially involved in the successful development and commercial launch of over 30 prescription products, 14 of which achieved blockbuster status. Prior to joining AVITA, Dr. Perry’s leadership positions included Chief Scientific Officer of Novartis’ Cell and Gene Therapy Unit from 2014-2017; Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp. from 2012-2014. With additional positions held as Global Head of R&D at Baxter Healthcare; President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc.; Vice President of Regulatory Affairs at Sandoz Pharmaceuticals Corporation; Director of Regulatory Affairs at Schering-Plough Corporation; and Venture Partner with Bay City Capital, LLC, Dr. Perry brings successful global management, guidance and forward direction to AVITA. Since 2011, has served as a Director with Arrowhead Pharmaceutical expanding his reach in influential medical growth.